Experimental Hematology
Volume 38, Issue 3 , Pages 213-221 , March 2010

B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression

  • Andrea Borgerding

      Affiliations

    • Department of Haematology and Oncology, Georg-August University of Göttingen, Göttingen, Germany
    • Corresponding Author InformationOffprint requests to: Andrea Borgerding, M.D., Department of Hematology and Oncology Georg-August University of Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany
    • ,
  • Justin Hasenkamp

      Affiliations

    • Department of Haematology and Oncology, Georg-August University of Göttingen, Göttingen, Germany
    • ,
  • Michael Engelke

      Affiliations

    • Department of Cellular and Molecular Immunology, Georg-August University of Göttingen, Göttingen, Germany
    • ,
  • Nina Burkhart

      Affiliations

    • Department of Haematology and Oncology, Georg-August University of Göttingen, Göttingen, Germany
    • ,
  • Lorenz Trümper

      Affiliations

    • Department of Haematology and Oncology, Georg-August University of Göttingen, Göttingen, Germany
    • ,
  • Jürgen Wienands

      Affiliations

    • Department of Cellular and Molecular Immunology, Georg-August University of Göttingen, Göttingen, Germany
    • ,
  • Bertram Glass

      Affiliations

    • Asklepios Clinic St. Georg, Department of Haematology and Stem Cell Transplantation, Hamburg, Germany

Received 6 October 2009 ,Revised 11 December 2009 ,Accepted 28 December 2009.

References 

  1. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927–1932
  2. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–3071
  3. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391
  4. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038–1043
  5. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101:949–954
  6. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–7368
  7. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007;233–242
  8. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007;67:1270–1281
  9. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383–3389
  10. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10:2253–2264
  11. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–758
  12. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64:4664–4669
  13. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–3947
  14. Flieger D, Renoth S, Beier I, et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000;204:55–63
  15. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634–641
  16. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2–9
  17. Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237–244
  18. Gunturi A, Berg RE, Forman J. The role of CD94/NKG2 in innate and adaptive immunity. Immunol Res. 2004;30:29–34
  19. Vilches C, Parham PKIR. diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217–251
  20. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–799
  21. Moretta A, Locatelli F, Moretta L. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev. 2008;224:58–69
  22. Daniels BF, Karlhofer FM, Seaman WE, et al. A natural killer cell receptor specific for a major histocompatibility complex class I molecule. J Exp Med. 1994;180:687–692
  23. Lanier LL, Corliss B, Phillips JH. Arousal and inhibition of human NK cells. Immunol Rev. 1997;155:145–154
  24. Malnati MS, Peruzzi M, Parker KC, et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science. 1995;267:1016–1018
  25. Hasenkamp J, Borgerding A, Uhrberg M, et al. Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors. Scand J Immunol. 2008;67:218–229
  26. Hasenkamp J, Borgerding A, Wulf G, et al. Resistance against natural killer cell cytotoxicity: analysis of mechanisms. Scand J Immunol. 2006;64:444–449
  27. Shafer-Weaver KA, Sayers T, Kuhns DB, et al. Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med. 2004;2:31
  28. Tejde A, Mathsson L, Ekdahl KN, et al. Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system. Clin Exp Immunol. 2004;137:521–528
  29. Lehmann C, Glass B, Zeis M, et al. Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity. Cancer Immunol Immunother. 1999;48:209–213
  30. Binyamin L, Alpaugh RK, Hughes TL, et al. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol. 2008;180:6392–6401
  31. Warren HS, Campbell AJ, Waldron JC, et al. Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors. Int Immunol. 2001;13:1043–1052
  32. Chewning JH, Gudme CN, Hsu KC, et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol. 2007;179:854–868
  33. Almeida CR, Davis DM. Segregation of HLA-C from ICAM-1 at NK cell immune synapses is controlled by its cell surface density. J Immunol. 2006;177:6904–6910
  34. Pfeiffer M, Schumm M, Feuchtinger T, et al. Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. Br J Haematol. 2007;138:97–100
  35. Stein MN, Shin J, Gudzowaty O, et al. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res. 2006;26:1759–1763
  36. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188–2195
  37. Bauernhofer T, Kuss I, Henderson B, et al. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol. 2003;33:119–124
  38. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331–342
  39. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486–5495
  40. Riond J, Rodriguez S, Nicolau ML, et al. In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun. 2009;9:10
  41. Sigidin YA, Loukina GV, Skurkovich B, et al. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol. 2001;30:203–207
  42. Skurkovich S, Boiko A, Beliaeva I, et al. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler. 2001;7:277–284

PII: S0301-472X(09)00488-3

doi: 10.1016/j.exphem.2009.12.007

Experimental Hematology
Volume 38, Issue 3 , Pages 213-221 , March 2010

Article Tools

* Image Usage & Resolution